Therapeutic Monoclonal Antibodies Market, Global Outlook and Forecast 2023-2029
Report ID
42807
Publisher
Market Monitor Global
Published Date
07-Dec
Delivery Format
PDF
No of Report Page
132
Editor's Rating
US $3,250.00
US $4,225.00
US $4,875.00
  • Report Details 
    This research report provides a comprehensive analysis of the Therapeutic Monoclonal Antibodies market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Therapeutic Monoclonal Antibodies market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Therapeutic Monoclonal Antibodies, challenges faced by the industry, and potential opportunities for market players.
The global Therapeutic Monoclonal Antibodies market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Therapeutic Monoclonal Antibodies market presents opportunities for various stakeholders, including Immune Diseases, Cancer. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Therapeutic Monoclonal Antibodies market. Additionally, the growing consumer demand present avenues for market expansion.
The global Therapeutic Monoclonal Antibodies market was valued at US$ 153180 million in 2022 and is projected to reach US$ 325140 million by 2029, at a CAGR of 11.6% during the forecast period.
The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.
Key Features:
The research report on the Therapeutic Monoclonal Antibodies market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Therapeutic Monoclonal Antibodies market.
Market Overview: The report provides a comprehensive overview of the Therapeutic Monoclonal Antibodies market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Mouse-derived Antibodies, Chimeric Antibodies), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Therapeutic Monoclonal Antibodies market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Therapeutic Monoclonal Antibodies market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Therapeutic Monoclonal Antibodies market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments. 
Market Segmentation and Forecast: The report segment the Therapeutic Monoclonal Antibodies market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Therapeutic Monoclonal Antibodies market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Therapeutic Monoclonal Antibodies market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Therapeutic Monoclonal Antibodies, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Therapeutic Monoclonal Antibodies market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Therapeutic Monoclonal Antibodies market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
    Mouse-derived Antibodies
    Chimeric Antibodies
    Humanized Antibodies
Market segment by Application
    Immune Diseases
    Cancer
    Other
Global Therapeutic Monoclonal Antibodies Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Major players covered
    AbbVie
    Johnson & Johnson
    Novartis
    Gilead Sciences
    Roche
    Bristol-Myers Squibb
    Amgen
    AstraZeneca
    Merck & Co
    Takeda
    Merck KGaA
    Seagen
    Eli Lilly
    Ono Pharmaceutical
    Pfizer
    Regeneron
    Innovent
    Hengrui Medicine
Outline of Major Chapters:
Chapter 1: Introduces the definition of Therapeutic Monoclonal Antibodies, market overview.
Chapter 2: Global Therapeutic Monoclonal Antibodies market size in revenue.
Chapter 3: Detailed analysis of Therapeutic Monoclonal Antibodies company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Therapeutic Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
  • Table Of Content 
    1 Introduction to Research & Analysis Reports
    1.1 Therapeutic Monoclonal Antibodies Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Therapeutic Monoclonal Antibodies Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Therapeutic Monoclonal Antibodies Overall Market Size
    2.1 Global Therapeutic Monoclonal Antibodies Market Size: 2022 VS 2029
    2.2 Global Therapeutic Monoclonal Antibodies Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Therapeutic Monoclonal Antibodies Players in Global Market
    3.2 Top Global Therapeutic Monoclonal Antibodies Companies Ranked by Revenue
    3.3 Global Therapeutic Monoclonal Antibodies Revenue by Companies
    3.4 Top 3 and Top 5 Therapeutic Monoclonal Antibodies Companies in Global Market, by Revenue in 2022
    3.5 Global Companies Therapeutic Monoclonal Antibodies Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Therapeutic Monoclonal Antibodies Players in Global Market
        3.6.1 List of Global Tier 1 Therapeutic Monoclonal Antibodies Companies
        3.6.2 List of Global Tier 2 and Tier 3 Therapeutic Monoclonal Antibodies Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Therapeutic Monoclonal Antibodies Market Size Markets, 2022 & 2029
        4.1.2 Mouse-derived Antibodies
        4.1.3 Chimeric Antibodies
        4.1.4 Humanized Antibodies
    4.2 By Type - Global Therapeutic Monoclonal Antibodies Revenue & Forecasts
        4.2.1 By Type - Global Therapeutic Monoclonal Antibodies Revenue, 2018-2023
        4.2.2 By Type - Global Therapeutic Monoclonal Antibodies Revenue, 2024-2029
        4.2.3 By Type - Global Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Therapeutic Monoclonal Antibodies Market Size, 2022 & 2029
        5.1.2 Immune Diseases
        5.1.3 Cancer
        5.1.4 Other
    5.2 By Application - Global Therapeutic Monoclonal Antibodies Revenue & Forecasts
        5.2.1 By Application - Global Therapeutic Monoclonal Antibodies Revenue, 2018-2023
        5.2.2 By Application - Global Therapeutic Monoclonal Antibodies Revenue, 2024-2029
        5.2.3 By Application - Global Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global Therapeutic Monoclonal Antibodies Market Size, 2022 & 2029
    6.2 By Region - Global Therapeutic Monoclonal Antibodies Revenue & Forecasts
        6.2.1 By Region - Global Therapeutic Monoclonal Antibodies Revenue, 2018-2023
        6.2.2 By Region - Global Therapeutic Monoclonal Antibodies Revenue, 2024-2029
        6.2.3 By Region - Global Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America Therapeutic Monoclonal Antibodies Revenue, 2018-2029
        6.3.2 US Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.3.3 Canada Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.3.4 Mexico Therapeutic Monoclonal Antibodies Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe Therapeutic Monoclonal Antibodies Revenue, 2018-2029
        6.4.2 Germany Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.4.3 France Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.4.4 U.K. Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.4.5 Italy Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.4.6 Russia Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.4.7 Nordic Countries Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.4.8 Benelux Therapeutic Monoclonal Antibodies Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia Therapeutic Monoclonal Antibodies Revenue, 2018-2029
        6.5.2 China Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.5.3 Japan Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.5.4 South Korea Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.5.5 Southeast Asia Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.5.6 India Therapeutic Monoclonal Antibodies Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America Therapeutic Monoclonal Antibodies Revenue, 2018-2029
        6.6.2 Brazil Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.6.3 Argentina Therapeutic Monoclonal Antibodies Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Therapeutic Monoclonal Antibodies Revenue, 2018-2029
        6.7.2 Turkey Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.7.3 Israel Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.7.4 Saudi Arabia Therapeutic Monoclonal Antibodies Market Size, 2018-2029
        6.7.5 UAE Therapeutic Monoclonal Antibodies Market Size, 2018-2029
7 Therapeutic Monoclonal Antibodies Companies Profiles
    7.1 AbbVie
        7.1.1 AbbVie Company Summary
        7.1.2 AbbVie Business Overview
        7.1.3 AbbVie Therapeutic Monoclonal Antibodies Major Product Offerings
        7.1.4 AbbVie Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.1.5 AbbVie Key News & Latest Developments
    7.2 Johnson & Johnson
        7.2.1 Johnson & Johnson Company Summary
        7.2.2 Johnson & Johnson Business Overview
        7.2.3 Johnson & Johnson Therapeutic Monoclonal Antibodies Major Product Offerings
        7.2.4 Johnson & Johnson Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.2.5 Johnson & Johnson Key News & Latest Developments
    7.3 Novartis
        7.3.1 Novartis Company Summary
        7.3.2 Novartis Business Overview
        7.3.3 Novartis Therapeutic Monoclonal Antibodies Major Product Offerings
        7.3.4 Novartis Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.3.5 Novartis Key News & Latest Developments
    7.4 Gilead Sciences
        7.4.1 Gilead Sciences Company Summary
        7.4.2 Gilead Sciences Business Overview
        7.4.3 Gilead Sciences Therapeutic Monoclonal Antibodies Major Product Offerings
        7.4.4 Gilead Sciences Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.4.5 Gilead Sciences Key News & Latest Developments
    7.5 Roche
        7.5.1 Roche Company Summary
        7.5.2 Roche Business Overview
        7.5.3 Roche Therapeutic Monoclonal Antibodies Major Product Offerings
        7.5.4 Roche Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.5.5 Roche Key News & Latest Developments
    7.6 Bristol-Myers Squibb
        7.6.1 Bristol-Myers Squibb Company Summary
        7.6.2 Bristol-Myers Squibb Business Overview
        7.6.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Major Product Offerings
        7.6.4 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.6.5 Bristol-Myers Squibb Key News & Latest Developments
    7.7 Amgen
        7.7.1 Amgen Company Summary
        7.7.2 Amgen Business Overview
        7.7.3 Amgen Therapeutic Monoclonal Antibodies Major Product Offerings
        7.7.4 Amgen Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.7.5 Amgen Key News & Latest Developments
    7.8 AstraZeneca
        7.8.1 AstraZeneca Company Summary
        7.8.2 AstraZeneca Business Overview
        7.8.3 AstraZeneca Therapeutic Monoclonal Antibodies Major Product Offerings
        7.8.4 AstraZeneca Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.8.5 AstraZeneca Key News & Latest Developments
    7.9 Merck & Co
        7.9.1 Merck & Co Company Summary
        7.9.2 Merck & Co Business Overview
        7.9.3 Merck & Co Therapeutic Monoclonal Antibodies Major Product Offerings
        7.9.4 Merck & Co Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.9.5 Merck & Co Key News & Latest Developments
    7.10 Takeda
        7.10.1 Takeda Company Summary
        7.10.2 Takeda Business Overview
        7.10.3 Takeda Therapeutic Monoclonal Antibodies Major Product Offerings
        7.10.4 Takeda Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.10.5 Takeda Key News & Latest Developments
    7.11 Merck KGaA
        7.11.1 Merck KGaA Company Summary
        7.11.2 Merck KGaA Business Overview
        7.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Major Product Offerings
        7.11.4 Merck KGaA Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.11.5 Merck KGaA Key News & Latest Developments
    7.12 Seagen
        7.12.1 Seagen Company Summary
        7.12.2 Seagen Business Overview
        7.12.3 Seagen Therapeutic Monoclonal Antibodies Major Product Offerings
        7.12.4 Seagen Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.12.5 Seagen Key News & Latest Developments
    7.13 Eli Lilly
        7.13.1 Eli Lilly Company Summary
        7.13.2 Eli Lilly Business Overview
        7.13.3 Eli Lilly Therapeutic Monoclonal Antibodies Major Product Offerings
        7.13.4 Eli Lilly Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.13.5 Eli Lilly Key News & Latest Developments
    7.14 Ono Pharmaceutical
        7.14.1 Ono Pharmaceutical Company Summary
        7.14.2 Ono Pharmaceutical Business Overview
        7.14.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Major Product Offerings
        7.14.4 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.14.5 Ono Pharmaceutical Key News & Latest Developments
    7.15 Pfizer
        7.15.1 Pfizer Company Summary
        7.15.2 Pfizer Business Overview
        7.15.3 Pfizer Therapeutic Monoclonal Antibodies Major Product Offerings
        7.15.4 Pfizer Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.15.5 Pfizer Key News & Latest Developments
    7.16 Regeneron
        7.16.1 Regeneron Company Summary
        7.16.2 Regeneron Business Overview
        7.16.3 Regeneron Therapeutic Monoclonal Antibodies Major Product Offerings
        7.16.4 Regeneron Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.16.5 Regeneron Key News & Latest Developments
    7.17 Innovent
        7.17.1 Innovent Company Summary
        7.17.2 Innovent Business Overview
        7.17.3 Innovent Therapeutic Monoclonal Antibodies Major Product Offerings
        7.17.4 Innovent Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.17.5 Innovent Key News & Latest Developments
    7.18 Hengrui Medicine
        7.18.1 Hengrui Medicine Company Summary
        7.18.2 Hengrui Medicine Business Overview
        7.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Major Product Offerings
        7.18.4 Hengrui Medicine Therapeutic Monoclonal Antibodies Revenue in Global Market (2018-2023)
        7.18.5 Hengrui Medicine Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer
  • Inquiry Before Buying

    Inquiry Before Buying

    Your personal details will remain secure and confidential - Privacy Policy

    WHY CHOOSE US

    Easy Access and Express Report Delivery Service
    Discover Business Growth Opportunities
    More than 10 Years Experience Employee Support
    In-depth and Comprehensive Analysis
    100+ Client Queries Handled Everyday
  • Request Sample

    Request For Sample

    Your personal details will remain secure and confidential - Privacy Policy

    WHY CHOOSE US

    Easy Access and Express Report Delivery Service
    Discover Business Growth Opportunities
    More than 10 Years Experience Employee Support
    In-depth and Comprehensive Analysis
    100+ Client Queries Handled Everyday


Our Trusted Clients
cooper.fr
koronos
waldenmedical
unioncomm.co.kr
technopathclinicaldiagnostics
toho-titanium.co.jp
straubmedical
sew-eurodrive.de
medurifarms
naperol
nvent
network.ae
petronas
saeedghodran
polyworldsys
seedplanning.co.jp
kraton
ipms.fraunhofer.de
infanttech
httpswww.castel-freres
hintoninfo
hexcel
freightways.co.nz
excelitas
Acco
aspet
brand
bmc
elevate
europ-assistance


GET IN TOUCH
Phone: +1 (415) 315-9432
Phone: +91 86698 89536
Email: inquiry@wiredrelease.com
SHORT NAVIGATION
connect with us